RxDoctor Payments Data

Rajan Kohli, MD

Family Medicine · Waxahachie, TXNPI 1477534436

Payments from drug & device makers

$2,104in general payments, 2019–2025

Across 89 payments — averaging $23.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$261
  • AstraZeneca$253
  • Amgen$212
  • Abbott$189
  • AbbVie$178
  • Merck$161
  • plus $850 from 21 others

What the payments were for

  • Food & beverage$2,104100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,104 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$170,341
Medicare patients
139
Services billed
4,493

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide48$42,495
EliquisApixaban35$34,100
MounjaroTirzepatide11$10,702
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$9,267
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$7,161
Varenicline Tartrate13$4,360
Breo ElliptaFluticasone/Vilanterol11$4,200
SymbicortBudesonide/Formoterol Fumarate15$3,292
Nifedipine ErNifedipine47$2,475
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen42$1,305
Albuterol Sulfate HfaAlbuterol Sulfate30$1,001
Losartan Potassium124$840
Atorvastatin Calcium105$730
Rosuvastatin Calcium40$690
Carvedilol87$657

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$52$42,49548 claims
PfizerEliquis$261$34,10035 claims
GSKTrelegy Ellipta, Breo Ellipta$17$13,46725 claims
Lilly USA, LLCMounjaro$64$10,70211 claims
AstraZenecaBreztri Aerosphere, Symbicort$253$10,45329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Waxahachie

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →